

# Ramesh Rengan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/181426/publications.pdf>

Version: 2024-02-01

127  
papers

5,975  
citations

109321

35  
h-index

76900

74  
g-index

130  
all docs

130  
docs citations

130  
times ranked

8933  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of ocular tumors through a novel applicator on a conventional proton pencil beam scanning beamline. <i>Scientific Reports</i> , 2022, 12, 4648.	3.3	5
2	Consensus Statement on Proton Therapy in Mesothelioma. <i>Practical Radiation Oncology</i> , 2021, 11, 119-133.	2.1	11
3	Radiation and Modulation of the Tumor Immune Microenvironment in Non-Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 133-139.	2.2	6
4	Radiation Treatment of Non-Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 95-96.	2.2	0
5	Phase II Trial of Flaxseed to Prevent Acute Complications After Chemoradiation for Lung Cancer. <i>Journal of Alternative and Complementary Medicine</i> , 2021, 27, 824-831.	2.1	3
6	Tumor control probability in hypofractionated radiotherapy as a function of total and hypoxic tumor volumes. <i>Physics in Medicine and Biology</i> , 2021, 66, 125010.	3.0	2
7	Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, 861-871.	1.3	9
8	Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry. <i>Advances in Radiation Oncology</i> , 2021, 7, 100767.	1.2	2
9	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. <i>OncImmunity</i> , 2021, 10, 1863631.	4.6	16
10	Prognostic value of early FDG PET response imaging and peripheral immunologic biomarkers: sub-study of a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer. <i>Advances in Radiation Oncology</i> , 2021, 7, 100857.	1.2	0
11	A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 170-177.	0.8	13
12	ACR-ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 545-552.	1.3	20
13	Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. <i>Annals of Translational Medicine</i> , 2020, 8, 482-482.	1.7	101
14	Volume effects in the TCP for hypoxic and oxygenated tumors. <i>Medical Physics</i> , 2020, 47, 4626-4633.	3.0	4
15	Scanning Beam Proton Therapy versus Photon IMRT for Stage III Lung Cancer: Comparison of Dosimetry, Toxicity, and Outcomes. <i>Advances in Radiation Oncology</i> , 2020, 5, 434-443.	1.2	9
16	Implementation of patient reported outcomes in definitive chemoradiation for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 154-155.	2.8	0
17	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 631-640.	0.8	40
18	Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared to Rectal Balloon Immobilization After Proton Beam Radiation Therapy for Localized Prostate Cancer: A Retrospective Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 635-643.	0.8	17

#	ARTICLE	IF	CITATIONS
19	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 146, 223-229.	0.6	168
20	Radiation Therapy in King County, Washington During the COVID-19 Pandemic: Balancing Patient Care, Transmission Mitigation, and Resident Training. <i>Advances in Radiation Oncology</i> , 2020, 5, 544-547.	1.2	19
21	COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation. <i>Brachytherapy</i> , 2020, 19, 401-411.	0.5	32
22	Sensitivity analysis of FDG PET tumor voxel cluster radiomics and dosimetry for predicting mid-chemoradiation regional response of locally advanced lung cancer. <i>Physics in Medicine and Biology</i> , 2020, 65, 205007.	3.0	7
23	Prognostic role of mid-treatment PET/CT and plasma cytokines in patients undergoing chemoradiation for locally advanced non-small cell lung cancer (LA-NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9040-9040.	1.6	0
24	Actionable policy barriers for receiving standard of care treatment among unresected stage III non-small cell lung cancer (NSCLC) patients in the United States.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2069-2069.	1.6	0
25	Concurrent and sequential chemoradiation therapy are associated with improved survival among unresected stage III non-small cell lung cancer patients in the United States.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7043-7043.	1.6	0
26	Comparison of regional lung perfusion response on longitudinal MAA SPECT/CT in lung cancer patients treated with and without functional tissue-avoidance radiation therapy. <i>British Journal of Radiology</i> , 2019, 92, 20190174.	2.2	14
27	Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-â€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1464.	7.1	28
28	Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 332-339.	2.8	8
29	Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients. <i>Practical Radiation Oncology</i> , 2019, 9, 305-321.	2.1	51
30	Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging. <i>Clinical Cancer Research</i> , 2019, 25, 5027-5037.	7.0	10
31	Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients With Uveal Melanoma Treated With Proton Beam Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 374-382.	0.8	1
32	Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. <i>Practical Radiation Oncology</i> , 2019, 9, 280-288.	2.1	31
33	Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience. <i>Advances in Radiation Oncology</i> , 2019, 4, 70-78.	1.2	5
34	Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-â€“small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location. <i>Clinical Lung Cancer</i> , 2019, 20, e63-e71.	2.6	36
35	4D computed tomography scans for conformal thoracic treatment planning: is a single scan sufficient to capture thoracic tumor motion?. <i>Physics in Medicine and Biology</i> , 2018, 63, 02NT03.	3.0	5
36	The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e205-e209.	2.6	3

#	ARTICLE	IF	CITATIONS
37	Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2003-2004.	1.6	4
38	Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 180-188.	2.8	28
39	Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 114-121.	2.8	32
40	Decision analytic modeling for the economic analysis of proton radiotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 122-133.	2.8	9
41	Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. <i>Translational Lung Cancer Research</i> , 2018, 8, 5-14.	2.8	27
42	Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes. <i>Radiation Oncology</i> , 2018, 13, 179.	2.7	4
43	Correlation of Functional Lung Heterogeneity and Dosimetry to Radiation Pneumonitis using Perfusion SPECT/CT and FDG PET/CT Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1255-1264.	0.8	17
44	The Practicality of ICRU and Considerations for Future ICRU Definitions. <i>Seminars in Radiation Oncology</i> , 2018, 28, 201-206.	2.2	4
45	Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?. <i>International Journal of Particle Therapy</i> , 2018, 5, 183-195.	1.8	15
46	Long-term results of a phase I/II trial of nelfinavir with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8552-8552.	1.6	0
47	First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 364-371.	2.6	38
48	Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 410-418.	2.0	24
49	Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy. <i>Medical Physics</i> , 2017, 44, 3418-3429.	3.0	55
50	Dose Escalation Optimization in Patients With Locally Advanced Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1365.	7.1	2
51	The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients. <i>Advances in Radiation Oncology</i> , 2017, 2, 192-196.	1.2	12
52	Prospective study of proton beam radiation therapy for limited-stage small cell lung cancer. <i>Cancer</i> , 2017, 123, 4244-4251.	4.1	60
53	(S010) Stereotactic Body Radiotherapy (SBRT) for Operable vs. Medically Inoperable Stage I Non-Small Cell Lung Cancer: Long-Term Five-Year Outcomes and an Assessment by Fractionation Regimen, Tumor Size, and Tumor Location. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, E3-E4.	0.8	1
54	Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 281-292.	1.1	82

#	ARTICLE	IF	CITATIONS
55	Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy. <i>Cureus</i> , 2017, 9, e1705.	0.5	10
56	Oligometastatic non-small-cell lung cancer: current treatment strategies. <i>Lung Cancer: Targets and Therapy</i> , 2016, Volume 7, 129-140.	2.7	11
57	Uncommon Thoracic Tumors. , 2016, , 865-894.e8.		0
58	Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 505-516.	0.8	125
59	Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 612-620.	0.8	49
60	Intratumoral G100 Rescues Radiation-Induced T Cell Depletion and Has Synergistic Anti-Tumor Effect with Local Irradiation in A20 Lymphoma. <i>Blood</i> , 2016, 128, 4166-4166.	1.4	1
61	Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions. <i>Cancers</i> , 2015, 7, 1178-1190.	3.7	37
62	Ill-posed problem and regularization in reconstruction of radiobiological parameters from serial tumor imaging data. <i>Physics in Medicine and Biology</i> , 2015, 60, 8491-8503.	3.0	10
63	Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study. <i>Practical Radiation Oncology</i> , 2015, 5, e355-e363.	2.1	18
64	Intensity-Modulated Proton Therapy for Elective Nodal Irradiation and Involved-Field Radiation in the Definitive Treatment of Locally Advanced Non-Small-Cell Lung Cancer: A Dosimetric Study. <i>Clinical Lung Cancer</i> , 2015, 16, 237-244.	2.6	54
65	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. <i>Nature</i> , 2015, 520, 373-377.	27.8	1,955
66	Education and Training Needs in Radiation Oncology in India: Opportunities for Indo-US Collaborations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 957-960.	0.8	3
67	Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 133-139.	0.8	17
68	Radiation Injury to the Normal Brain Measured by 3D Echo-Planar Spectroscopic Imaging and Diffusion Tensor Imaging: Initial Experience. <i>Journal of Neuroimaging</i> , 2015, 25, 97-104.	2.0	35
69	Abstract 2858: Radiation and dual immune checkpoint blockade overcome tumor resistance and distinctly improve immunity. , 2015, , .		0
70	Abstract A52: Radiation and dual PD-L1 and CTLA4 checkpoint blockade non-redundantly improves tumor resistance, response, and immunity. , 2015, , .		0
71	Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate. <i>Oncology Letters</i> , 2014, 7, 1151-1158.	1.8	13
72	Dynamic simulation of motion effects in IMAT lung SBRT. <i>Radiation Oncology</i> , 2014, 9, 225.	2.7	28

#	ARTICLE	IF	CITATIONS
73	Stereotactic Body Radiotherapy. <i>Seminars in Oncology</i> , 2014, 41, 776-789.	2.2	22
74	The Use of Proton Therapy in the Treatment of Lung Cancers. <i>Cancer Journal (Sudbury, Mass )</i> , 2014, 20, 427-432.	2.0	57
75	Prognostic Value of Primary Tumor FDG Uptake for Occult Mediastinal Lymph Node Involvement in Clinically N2/N3 Node-negative Non-“Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 135-139.	1.3	14
76	Stage Migration in Planning PET/CT Scans in Patients Due to Receive Radiotherapy for Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 79-85.	2.6	61
77	Combination of stereotactic ablative body radiation with targeted therapies. <i>Lancet Oncology</i> , The, 2014, 15, e426-e434.	10.7	32
78	Impact of sociodemographic factors on the radiotherapeutic management of lung cancer: Results of a Quality Research in Radiation Oncology Survey. <i>Practical Radiation Oncology</i> , 2014, 4, e167-e179.	2.1	3
79	International Outreach: What Is the Responsibility of ASTRO and the Major International Radiation Oncology Societies?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 481-484.	0.8	11
80	An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer. <i>Radiation Oncology</i> , 2013, 8, 144.	2.7	39
81	Predicting Esophagitis After Chemoradiation Therapy for Non-Small Cell Lung Cancer: An Individual Patient Data Meta-Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 690-696.	0.8	157
82	Brachial Plexopathy in Apical Non-Small Cell Lung Cancer Treated With Definitive Radiation: Dosimetric Analysis and Clinical Implications. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 175-181.	0.8	36
83	Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 444-450.	0.8	545
84	A moving target: Image guidance for stereotactic body radiation therapy for early-stage non-small cell lung cancer. <i>Practical Radiation Oncology</i> , 2013, 3, 307-315.	2.1	43
85	High body mass index is associated with worse quality of life in breast cancer patients receiving radiotherapy. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 125-133.	2.5	29
86	Impact of PET Staging in Limited-Stage Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 899-905.	1.1	49
87	Role of particle beam therapy in a trimodality approach to locally advanced non-“small cell lung cancer. <i>Thoracic Cancer</i> , 2013, 4, 95-101.	1.9	2
88	Stereotactic Body Radiation Therapy for Lung Cancer. <i>Chest</i> , 2013, 143, 1784-1790.	0.8	87
89	Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. <i>Aids</i> , 2013, 27, 459-468.	2.2	86
90	Multi-institutional study of reirradiation with proton beam radiotherapy for non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7578-7578.	1.6	3

#	ARTICLE	IF	CITATIONS
91	Dietary Flaxseed in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation. Journal of Pulmonary & Respiratory Medicine, 2013, 03, 154.	0.1	2
92	Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235. Molecular Pharmacology, 2012, 82, 1230-1240.	2.3	78
93	A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response. Journal of Thoracic Oncology, 2012, 7, 709-715.	1.1	68
94	Definitive Radiotherapy for Unresected Adenoid Cystic Carcinoma of the Trachea. Chest, 2012, 141, 1323-1326.	0.8	42
95	The Impact of Extent and Location of Mediastinal Lymph Node Involvement on Survival in Stage III Non-Small Cell Lung Cancer Patients Treated With Definitive Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 340-347.	0.8	15
96	Effect of Body Mass Index on Magnitude of Setup Errors in Patients Treated With Adjuvant Radiotherapy for Endometrial Cancer With Daily Image Guidance. International Journal of Radiation Oncology Biology Physics, 2012, 83, 670-675.	0.8	44
97	Central-Airway Necrosis after Stereotactic Body-Radiation Therapy. New England Journal of Medicine, 2012, 366, 2327-2329.	27.0	134
98	Radiation Dosimetry and Biodistribution of the Hypoxia Tracer 18F-EF5 in Oncologic Patients. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 412-419.	1.0	15
99	Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncology, The, 2012, 13, 1203-1209.	10.7	50
100	Uncommon Thoracic Tumors. , 2012, , 859-889.		2
101	Definitive thoracic radiotherapy in oligometastatic stage IV non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, e18032-e18032.	1.6	0
102	Disparities in the treatment and outcomes of lung cancer among HIV-infected people in Texas.. Journal of Clinical Oncology, 2012, 30, 6070-6070.	1.6	0
103	Impact of PET staging in limited-stage SCLC.. Journal of Clinical Oncology, 2012, 30, 7098-7098.	1.6	0
104	A strategy to reduce acute toxicity from chemoradiation therapy for limited-stage small cell lung cancer.. Journal of Clinical Oncology, 2012, 30, e17534-e17534.	1.6	0
105	Case-control study of prophylactic cranial irradiation in nonmetastatic non-small cell lung cancer.. Journal of Clinical Oncology, 2012, 30, 7050-7050.	1.6	0
106	Addressing connectivity issues: The Integrating the Healthcare Enterprise-Radiation Oncology (IHE-RO) initiative. Practical Radiation Oncology, 2011, 1, 226-231.	2.1	10
107	A Glimpse of the Future. Cancer Journal (Sudbury, Mass ), 2011, 17, 190-194.	2.0	4
108	Adjuvant radiotherapy for completely resected stage 2 thymoma. Cancer, 2011, 117, 3502-3508.	4.1	35



#	ARTICLE	IF	CITATIONS
109	New Strategies in Non-“Small Cell Lung Cancer: Improving Outcomes in Chemoradiotherapy for Locally Advanced Disease. <i>Clinical Cancer Research</i> , 2011, 17, 4192-4199.	7.0	17
110	The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1454-1460.	1.1	58
111	Adjuvant Cisplatin and Docetaxel for Non-small Cell Lung Cancer: The Hospital of the University of Pennsylvania Experience. <i>Journal of Thoracic Oncology</i> , 2010, 5, 667-672.	1.1	6
112	Integrating the Healthcare Enterprise in Radiation Oncology Plug and Play-“The Future of Radiation Oncology?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 333-336.	0.8	19
113	Introduction: Non-“Small-Cell Lung Cancer and Pleural Malignancies: The End of the Era of Therapeutic Nihilism?. <i>Seminars in Radiation Oncology</i> , 2010, 20, 147-148.	2.2	5
114	Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. <i>Cancer Biology and Therapy</i> , 2010, 10, 425-429.	3.4	29
115	Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes. <i>Radiotherapy and Oncology</i> , 2010, 95, 178-184.	0.6	79
116	Hemithoracic Radiotherapy After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Dosimetric Comparison of Two Well-Described Techniques. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1431-1437.	1.1	18
117	Clinical target promiscuity: lessons from ras molecular trials. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 403-414.	5.9	18
118	New Approaches to Radiotherapy as Definitive Treatment for Inoperable Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2008, 20, 188-197.	0.6	9
119	Long-term Neck Control Rates After Complete Response to Chemoradiation in Patients With Advanced Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 465-469.	1.3	17
120	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. <i>Translational Lung Cancer Research</i> , 2007, 6, 169-177.	2.8	4
121	Ten-Year Results of Preoperative Radiation Followed by Sphincter Preservation for Rectal Cancer: Increased Local Failure Rate in Nonresponders. <i>Clinical Colorectal Cancer</i> , 2006, 5, 413-421.	2.3	15
122	Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-“small-cell lung cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 70-75.	0.8	149
123	Distal cT2N0 Rectal Cancer: Is There an Alternative to Abdominoperineal Resection?. <i>Journal of Clinical Oncology</i> , 2005, 23, 4905-4912.	1.6	48
124	Improved local control with higher doses of radiation in large-volume stage III non-“small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 741-747.	0.8	146
125	Actin cytoskeletal function is spared, but apoptosis is increased, in WAS patient hematopoietic cells. <i>Blood</i> , 2000, 95, 1283-1292.	1.4	83
126	Regulation of Oscillations in Filamentous Actin Content in Polymorphonuclear Leukocytes Stimulated with Leukotriene B4 and Platelet-Activating Factor. <i>Biochemical and Biophysical Research Communications</i> , 1999, 262, 479-486.	2.1	9



#	ARTICLE	IF	CITATIONS
127	Can we predict reactivity for aromatic nucleophilic substitution with [18F]fluoride ion?. Journal of Labelled Compounds and Radiopharmaceuticals, 1993, 33, 563-572.	1.0	14